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Introduction
Coronaviruses (CoVs) are viruses with a single-strand, positive-sense RNA
genome that is approximately 30 kilobases, the largest known RNA virus
genome.
The genome of SARS-CoV-2, the virus responsible for the current pandemic,
contains 82% nucleotide identity with human SARS-CoV, and 88% nucleotide
identity with 2 bat derived SARS-like coronaviruses. Therefore the virus is
thought to have originated in bats but transmitted to humans through some
intermediate mammal. Human SARS-CoV-2 was sequenced against the
Pangolin-CoV virus to determine whether the pangolin could be the intermediate
for human SARS-CoV-2, however the bat CoV was more similar to human SARSCoV-2 than Pangolin-CoV. Human SARS-CoV-2 was also shown to have a
unique peptide sequence insertion that the Pangolin-CoV does not share.
Therefore, human SARS-CoV-2’s intermediate host is still unknown.

Introduction Continued
Though human coronavirus infections generally involve the upper respiratory tract,
SARS-CoV-2 patients do not tend to show prominent upper respiratory tract
symptoms, indicating that SARS-CoV-2 target cells are in the lower respiratory
tract. The most common symptoms of COVID-19 appear to be fever, cough, and
fatigue, with pneumonia often developing as well. The virus has been found to be
primarily transmitted through person-to-person contact, particularly through those
that are infected, but asymptomatic.
Patients with SARS-CoV-2 test positive, starting from the onset of symptoms, for a
median of 16 days, with 26.3% testing positive after 4 weeks. This indicates that
the viral replication in SARS-CoV-2 has a relatively long period compared to that
of SARS-CoV. Studies also show that SARS-CoV-2 can be detected in the fecal
matter of a recovered patient up to 10 days after the nasal test comes back
negative, indicating the patient can stay contagious longer than originally thought.

Potential Treatments
One theory on a treatment for COVID-19 is angiotension-converting enzyme
inhibitors (ACE inhibitors). ACE inhibitors block ACE2 receptors, which could
protect against a SARS-CoV-2 infection. ACE inhibitors have both pros and cons,
however. For example, ACE inhibitors inhibit ACE which leads to decreased
angiotension I levels. This can cause a negative feedback loop which would
ultimately increase ACE2 receptors, leading to more binding sites for the SARSCoV-2 virus.
Some argue, however, that ACE inhibitors are beneficial. Some arguments are
that the stimulation of negative feedback in ACE would reduce inflammation, while
some argue that ACE inhibitors impair the ACE receptor pathway, making it harder
for SARS-CoV-2 to bind to the receptor.
Another study showed no detectable difference in the virus progression between
those treated with ACE inhibitors and those not treated with ACE inhibitors.
Another potential treatment that has been explored is the binding affinity of 27
ligands occurring naturally in many cuisines to SARS-CoV-2 proteases. If any bind
successfully, they could potentially prevent the virus from replicating. This study
found that 15 of the 27 ligands were successful in binding to the viral proteases
and therefore successful in hindering viral replication. More research would need
to be done to recommend these natural ligands as a viral treatment, but the
preliminary research was positive.

Antibody Testing
Figure 1: Current phylogenetic tree for known coronaviruses
Y. Chen, Q. Liu and D. Guo, "Emerging coronaviruses: Genome structure, replication,
and pathogenesis," Journal of Medical Virology, vol. 92, no. 4, pp. 418-423, 2020.

SARS-CoV-2, like SARS-CoV, enters T lymphocytes using its spike protein to
interact with the human angiotension-converting enzyme 2 (ACE2) as its
receptor. SARS-CoV-2 was found to have a unique peptide sequence that could
contribute to the proteolytic cleavage of the spike protein, therefore potentially
impacting host range and transmissibility. In previous research of SARS-CoV, it
was found that in order for the virus to enter a host cell, an endocytic, proteaseprimed cleavage event must occur. This is different from most coronavirus fusion
proteins in that most are primed during assembly of the virus or upon release
from the cell.

Scanning electron microscope image of SARS-CoV-2 (yellow)
emerging from cells (blue and pink)

A blood test for SARS-CoV-2 specific antibodies would be simple, rapid, and
sensitive option for diagnosis of COVID-19 as well as determining if one has been
exposed to the virus and has been able to develop the antibodies to the virus.
IgM can be detected in the blood 3-6 days after exposure to SARS-CoV, and IgG
can be detected after 8 days. Since SARS-CoV-2 is so similar to SARS-CoV, a
SARS-CoV-2 IgG-IgM combined antibody test was developed under the
assumption that SARS-CoV-2 follows the same pattern. The combined IgG-IgM
test also allows for widespread testing for asymptomatic carriers.

https://www.niaid.nih.gov/news-events/novel-coronavirus-sarscov2-images
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The most common means of diagnosis for COVID-19 is real time quantitative
polymerase chain reaction, or RT-qPCR using a nasal swab. Unfortunately, the
sensitivity of RT-qPCR is only 50%-79%, meaning there are quite a few false
negatives. Chest CT scans are far more sensitive for diagnosis of COVID-19,
however they also come with shortcomings such as not being able to distinguish
between COVID-19 or some other viral pneumonia. ELISA kits are also being
developed by some companies and studies show that the ELISA is much more
sensitive than RT-qPCR as well, but they are still being tested.

SARS-CoV-2 is the virus responsible for the current COVID-19 pandemic. SARSCoV-2 is a betacoronavirus with a genome that is 82% identical to SARS-CoV.
The virus enters T lymphocytes using its spike protein with the human
angiotension-converting enzyme 2 as its receptor. COVID-19 is diagnosed
through a nasal swab SARS-CoV-2 RT-PCR assay and the most common
symptoms appear to be fever, cough, and fatigue. The median amount of time an
individual will be contagious with the virus is 16 days. Many possible treatment
methods have been explored including a SARS-CoV-2 specific antibody that
could be potentially therapeutic against the virus, natural remedies, and ACE
inhibitors. There are also IgM-IgG tests being developed that detect the
antibodies against SARS-CoV-2 virus in the blood that could help determine
transmission of the virus in the population as well as lead to more rapid, sensitive
diagnosis.
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